Michael Tukjer

In this engaging discussion, economics journalist Michael Tukjer sheds light on how Novo Nordisk's weight-loss drug, Ozempic, is a financial powerhouse for Denmark. Writer Josh Barrow dives into Ozempic's booming popularity and its profound societal impacts. They explore the economic dependency of cities revitalized by job creation from the pharmaceutical giant. The conversation also touches on the changing dynamics of consumer behavior and the potential future of obesity treatment in America, as these drugs reshape the healthcare landscape.